{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:46:16Z","timestamp":1792658776763,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1025,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.ijid.2010.06.016","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T10:07:53Z","timestamp":1285754873000},"page":"e1013-e1017","source":"Crossref","is-referenced-by-count":19,"title":["Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study"],"prefix":"10.1016","volume":"14","author":[{"given":"Weerawat","family":"Manosuthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preecha","family":"Tantanathip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanya","family":"Chimsuntorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boonchuay","family":"Eampokarap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supeda","family":"Thongyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samruay","family":"Nilkamhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnuek","family":"Sungkanuparph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2010.06.016_bib0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.qai.0000230521.86964.86","article-title":"Survival rate and risk factors of mortality among HIV\/tuberculosis-coinfected patients with and without antiretroviral therapy","volume":"43","author":"Manosuthi","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2010.06.016_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0b013e31819367e7","article-title":"Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis","volume":"50","author":"Velasco","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2010.06.016_bib0015","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":"Timing of initiation of antiretroviral drugs during tuberculosis therapy","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2010.06.016_bib0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/COH.0b013e3283339309","article-title":"Management of individuals requiring antiretroviral therapy and TB treatment","volume":"5","author":"Cohen","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijid.2010.06.016_bib0025","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1517\/17425250903393752","article-title":"Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all","volume":"6","author":"Kwara","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.ijid.2010.06.016_bib0030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijid.2010.06.016_bib0035","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(94)90693-9","article-title":"Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. The Makerere University\u2013Case Western University Research Collaboration","volume":"344","author":"Okwera","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2010.06.016_bib0040","unstructured":"Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: Department of Heath and Human Services and the Henry J. Kaiser Family Foundation; 2009."},{"key":"10.1016\/j.ijid.2010.06.016_bib0045","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/135965350501000809","article-title":"Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis","volume":"10","author":"Autar","year":"2005","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2010.06.016_bib0050","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1177\/135965350801300414","article-title":"Pharmacokinetics and 48-week efficacy of nevirapine: 400mg versus 600mg per day in HIV\u2013tuberculosis coinfection receiving rifampicin","volume":"13","author":"Avihingsanon","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2010.06.016_bib0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.aids.0000196181.18916.9b","article-title":"Efavirenz 600mg\/day versus efavirenz 800mg\/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results","volume":"20","author":"Manosuthi","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2010.06.016_bib0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/135965350701200406","article-title":"Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians","volume":"12","author":"van Oosterhout","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.ijid.2010.06.016_bib0065","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1468-1293.2008.00563.x","article-title":"Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin","volume":"9","author":"Manosuthi","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/j.ijid.2010.06.016_bib0070","first-page":"360","article-title":"Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB\u2013HIV co-infection in Botswana","volume":"13","author":"Shipton","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijid.2010.06.016_bib0075","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1086\/599114","article-title":"A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study","volume":"48","author":"Manosuthi","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2010.06.016_bib0080","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/jama.300.5.530","article-title":"Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy","volume":"300","author":"Boulle","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2010.06.016_bib0085","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1086\/505210","article-title":"Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin","volume":"43","author":"Manosuthi","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2010.06.016_bib0090","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1471-2334-8-136","article-title":"Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with\/without prior co-administration of rifampicin: a 144-week prospective study","volume":"8","author":"Manosuthi","year":"2008","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijid.2010.06.016_bib0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1183\/09031936.98.12020505","volume":"12","author":"Veen","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijid.2010.06.016_bib0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","article-title":"Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration","volume":"42","author":"Ramachandran","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijid.2010.06.016_bib0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/dkm484","article-title":"Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis","volume":"61","author":"Cohen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2010.06.016_bib0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1086\/510078","article-title":"Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis","volume":"44","author":"Manosuthi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2010.06.016_bib0115","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1164\/rccm.200509-1529OC","article-title":"Treatment outcomes of patients with HIV and tuberculosis","volume":"175","author":"Nahid","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2010.06.016_bib0120","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1086\/651686","article-title":"Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis","volume":"50","author":"Khan","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2010.06.016_bib0125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971210024598?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971210024598?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T14:45:00Z","timestamp":1685803500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971210024598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S1201971210024598"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2010.06.016","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}